Assistant Director, Flow and Image Cytometry Facility
Roswell Park Cancer Institute

Assistant Professor of Oncology
Division of Medicine, Roswell Park Cancer Institute

Dr. Hans Minderman joined the team of the Experimental Therapeutics Department at Roswell Park Cancer Institute in 1990. He was named the Assistant Director, Flow and Image Cytometry Facility in 2007. He earned his doctoral degree in Medical Biology at the University Hospital Nijmegen, The Netherlands (1994).  

Dr. Minderman's research interests include the clinical application of imaging flow cytometry, identification of methods to enhance treatment response in leukemia and lymphoma and the elucidation of multidrug resistance mechanisms.  

Dr. Minderman is a member of the American Association for Cancer Research and a member of the Cancer and Leukemia Group B (CALGB). He has authored or co-authored more than 90 journal publications, abstracts or book chapters.

The Flow and Image Cytometry Facility provides standard and advanced flow cytometry capabilities for research and clinical investigations at RPCI. It is a licensed reference laboratory for classification of leukemias and lymphomas by immunophenotyping, for evaluating immunologically-based diseases, for monitoring transplant patients, and for evaluating DNA in solid tumors. It is committed to translational research through the development of new tests. Standard and advanced flow and image cytometry services and capabilities also are provided to basic research scientists.

Key Publications

• Minderman H, Conroy JM, O'loughlin KL, McQuaid D, Quinn P, Li S, Pendyala L, Nowak NJ, Baer MR. In vitro and in vivo irinotecan-induced changes in expression profiles of cell cycle and apoptosis-associated genes in acute myeloid leukemia cells. Mol Cancer Ther, 4(6):885-900, 2005.
• Qadir M, O'Loughlin KL, Fricke SM, Williamson NA, Greco WR, Minderman H, Baer MR. Cyclosporine A is a broad-spectrum multidrug resistance modulator. Clinical Cancer Research, 11(6):2320-6, 2005.
• Minderman H, O'Loughlin KL, Smith P, Pendyala L, Greco WR, Sweeney K, Ford L, Wetzler M, Baer MR. Sequential Administration of Irinotecan and Cytarabine in the Treatment of Relapsed and Refractory Acute Myeloid Leukemia. Cancer Chemother Pharmacol. 57: 73-83, 2006.
• Pawarode A, Shukla S, Minderman H, Fricke SM, Pinder EM, O’Loughlin KL, Ambudkar SV, Baer MR. Differential Effects of the Immunosuppressive Agents Cyclosporin A, Tacrolimus and Sirolimus on Drug Transport by Multidrug Resistance Proteins. Cancer Chemotherapy and Pharmacology, in print Sept 2006.
• Minderman H, Zhou Y, O’Loughlin KL, Baer MR. Bortezomib activity and in vitro interactions with anthracyclines or cytarabine in acute myeloid leukemia cells are independent of multidrug resistance mechanisms and p53 status. Cancer Chemotherapy and Pharmacology, in print October, 2006.
• Brooks TA, O’Loughlin KL, Minderman H, Bundy B, Ford LA, Vredenburg MR, Bernacki RJ, Priebe W, Baer MR. The 4’-O-Benzylated Doxorubicin analog WP744 overcomes resistance mediated by P-Glycoprotein, Multidrug Resistance Protein and Breast Cancer Resistance protein in cell lines and acute myeloid leukemia cells. Invest New Drugs 25(2): 115-122, 2007.
• Huang RY, Kowalski D, Minderman H, Gandhi N, Johnson ES. Small ubiquitin-related modifier pathway is a major determinant of doxorubicin cytotoxicity in Saccharomyces cerevisiae. Cancer Res, in print January 2007.